<DOC>
	<DOCNO>NCT01147744</DOCNO>
	<brief_summary>To evaluate efficacy , dose response safety four dos GSK2190915 tablet form ( 10mg , 30mg , 100mg 300mg ) administer daily , 8 week compare placebo adolescent adult subject ( 12 year age old ) persistent asthma . These data form basis selection optimal daily dose GSK2190915 carry forward Phase III asthma study . The study also include Fluticasone Propionate Inhalation Powder ( 100 mcg , twice daily ) Montelukast ( 10mg , daily ) allow exploratory analysis efficacy GSK2190915 versus low dose inhale corticosteroid leukotriene receptor antagonist .</brief_summary>
	<brief_title>Dose Ranging Study Evaluating Efficacy Safety GSK2190915 Administered Once Daily</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>Type Subject : Outpatient Age : ≥12 year age Gender : Eligible Female ( female childbearing potential must commit consistent correct use acceptable method birth control ) Asthma Diagnosis : As define NIH Severity Disease : FEV1 5085 % predict AND current former smoker post salbutamol/albuterol ratio &gt; 0.70 Reversibility : ≥12 % ≥200mL FEV1 within 30 ±15 minute follow salbutamol/albuterol Current antiasthma therapy : Using shortacting betaagonist ( SABA ) ≥3 month Tobacco use : Nonsmoker /former smoker ≤10 pack year current smoker ≤10 pack year QTC : QTc ( F ) &lt; 450msec QTc ( F ) &lt; 480 subject Bundle Branch Block Liver function : Normal liver function Informed Consent History Lifethreatening asthma : Within previous 5 year Asthma Exacerbation : Requiring OCS within 3 month hospitalisation within 6 month Respiratory Infection : Not resolve within 4 week V1 AND lead change asthma management OR treatment antibiotic OR expect affect subject 's asthma status ability participate Corticosteroid Use : ICS use within 6 week OCS/depot corticosteroid within 12 week OATP1B1 substrate : OATP1B1 substrate ( e.g . statin , rifampicin , bromosulphophthalein , benzylpenicillin , methotrexate ) within 4 week Immunosuppressive medication : Either use require study Liver disease : Current chronic history Concurrent disease/abnormalities : Clinically significant uncontrolled disease Investigational medication : Participation study use investigational drug within 30 day Drug allergy : βagonists , corticosteroid , constituent inhaler Milk Protein Allergy : History severe milk protein allergy Compliance : Factors likely impair compliance either regard study medication , procedure attendance Unable unwilling follow instruction : Procedures , dose direction , ediaries pMDIs History alcohol drug abuse : Likely interfere study Affiliation Investigator 's Site : Relative employee</criteria>
	<gender>Female</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Efficacy</keyword>
	<keyword>Asthma</keyword>
	<keyword>Safety</keyword>
	<keyword>Fluticasone Propionate</keyword>
	<keyword>FLAP</keyword>
	<keyword>Beta-agonists</keyword>
	<keyword>GSK2190915</keyword>
	<keyword>Montelukast</keyword>
	<keyword>Placebo</keyword>
	<keyword>FLAIR</keyword>
</DOC>